The effect of long-term antithrombotic therapies on perioperative morbidity and mortality in elderly patients undergoing hip fracture surgery

Yıl 2022, Cilt: 32 Sayı: 3, 229 - 237, 01.08.2022

Güzin Ceran , Ayşe Lafçı , İsmail Aytaç , Gazi Akkurt , Nermin Göğüş , Derya Gokcinar

https://doi.org/10.54005/geneltip.1097997

Öz

ABSTRACT
Objective: Ischemic complications or massive bleeding are important perioperative complications in elderly patients using antithrombotic drugs. The need for blood product replacement, transfusion-related complications, prolonged stay in hospital and intensive care unit, and high mortality in the perioperative period can be seen. The aim of this study was to investigate the effects of long-term different antithrombotic therapies on morbidity and mortality in elderly patients undergoing surgery for hip fracture.
Materials and Methods: This retrospective cohort study included patients aged 65 years and older who underwent surgery for hip fracture between 2015 and 2018. Patients with no antithrombotic treatment (Group NonAT), warfarin (Group Warfarin), novel oral anticoagulants (Group NOACs), or dual antiplatelet therapy (Group DAPT) were compared in terms of major bleeding, deep venous thrombosis (DVT) and pulmonary thromboembolism (PTE) complications, length of hospital stay (LOS), ICU admission, and 30-day mortality.
Results: The study included 668 patients; demographic data in Group NonAT (n=442), Group Warfarin (n=59), Group NOACs (n=30) and Group DAPT(n=137) were similar. Major bleeding and red blood cell transfusion did not differ statistically between all groups. (p>0.05) The preoperative and postoperative Hb values of the patients were not statistically different between the groups (p>0.05). Mortality, only there was statistically significantly higher in the dual antiplatelet group than the non user group. (p<0.05) In terms of survival, multivariate analysis showed no difference between the groups. (p>0.05) However survival was statistically significant different (p<0.05) in terms of the PTE and admission to ICU. Kaplan-Meier survival analysis showed that patients in the group NonAT have longer survival times than patients in the group warfarin, group NOACs, or group DAPT.
Conclusion: In this study, we found that the effects of antithrombotic drug classes (warfarin, new oral anticoagulants or dual antiplatelet therapy) on mortality were not different. Mortality rate was higher only in the dual antiplatelet group than in the no drug group. It is important to discontinue these drugs at the timing according to their half-lives and elimination times. Effective bridging therapy should be applied in the perioperative period. Thus, the risk of major bleeding or complications of DVT and PTE can be avoided. New bridging strategies should be researched in patients using antiplatelets.

Anahtar Kelimeler

Hip fracture, elderly patient, warfarin, novel oral anticoagulants, dual antiplatelets

Kalça kırığı cerrahisi geçiren yaşlı hastalarda uzun dönem antitrombotik tedavilerin perioperatif morbidite ve mortalite üzerine etkisi

Öz

Amaç: Antitrombotik ilaç kullanan yaşlı hastalarda, iskemik komplikasyonlar veya masif kanama önemli perioperatif komplikasyonlardır. Kan ürünü replasmanı ihtiyacı, transfüzyona bağlı komplikasyonlar, hastanede ve yoğun bakımda kalış süresinin uzaması ve perioperatif dönemde yüksek mortalite görülebilmektedir. Bu çalışmanın amacı, kalça kırığı nedeniyle ameliyat edilen yaşlı hastalarda uzun süreli farklı antitrombotik tedavilerin morbidite ve mortalite üzerine etkilerini araştırmaktır.
Gereç ve Yöntem: Bu retrospektif kohort çalışmasına 2015 ve 2018 yılları arasında kalça kırığı nedeniyle ameliyat edilen 65 yaş ve üstü hastalar dahil edilmiştir. Antitrombotik tedavi almayan hastalar (Grup NonAT), varfarin (Grup Warfarin), yeni oral antikoagülanlar (Grup NOAC'ler) veya ikili antiplatelet tedavi (Grup DAPT) alan hasta grupları majör kanama, derin ven trombozu (DVT) ve pulmoner tromboembolizm (PTE) komplikasyonları, hastanede kalış süresi (LOS), yoğun bakım ünitesine yatış ve 30 günlük mortalite açısından karşılaştırıldı.
Bulgular: Çalışmaya 668 hasta dahil edildi; Grup NonAT(n=442), Grup Warfarin (n=59), Grup NOACs (n=30) ve Grup DAPT(n=137) hasta demografik verileri benzerdi. Majör kanama ve kırmızı kan hücresi transfüzyonu tüm gruplar arasında istatistiksel olarak fark yoktu. (p>0.05) Hastaların ameliyat öncesi ve sonrası Hb değerleri gruplar arasında istatistiksel olarak farklı değildi (p>0.05). Ölüm oranı, sadece ikili antiplatelet grubunda, hiç ilaç kullanmayan gruba göre istatistiksel olarak anlamlı derecede yüksekti. (p<0.05) Sağkalım açısından multivariate analysis gruplar arasında fark göstermedi. (p>0.05) Ancak sağ kalım PTE ve YBÜ'ye yatış açısından istatistiksel olarak anlamlı farklılık gösterdi (p<0.05). Kaplan-Meier yaşam analizi, NonAT grubundaki hastaların varfarin, grup NOACs veya grup DAPT'deki hastalardan daha uzun hayatta kalma sürelerine sahip olduğunu gösterdi.
Sonuç: Bu çalışmada, antitrombotik ilaç sınıflarının (varfarin, yeni oral antikoagülanlar veya ikili antiplatelet tedavi) mortalite üzerindeki etkilerinin farklı olmadığını bulduk. Ölüm oranı, sadece ikili antiplatelet grubunda, hiç ilaç kullanmayan gruba göre daha yüksekti. Bu ilaçların yarılanma ömürlerine ve eliminasyon sürelerine göre preoperatif kesilmesi önemlidir. Perioperatif dönemde etkin köprüleme tedavisi uygulanmalıdır. Böylece majör kanama veya DVT ve PTE komplikasyonları riskinden kaçınılabilir. Antiplatelet kullanan hastalarda yeni köprüleme stratejileri araştırılmalıdır.

Anahtar Kelimeler

Kalça kırığı, yaşlı hasta, warfarin, yeni oral antikoagülanlar, dual antiplateletler

Kaynakça

• 1. de Jong L, van Rijckevorsel V, Klem TMAL, Kuijper M, Roukema GR. Prospective cohort protocol examining the perioperative indicators for complications and early mortality following hip fracture surgery in the frail patient. BMJ Open. 2020 Sep 29;10(9):e038988.
• 2. Bohm E, Loucks L, Wittmeier K, Lix LM, Oppenheimer L. Reduced time to surgery improves mortality and length of stay following hipfracture: results from an intervention study in a Canadian health authority. Canadian Journal of Surgery 2015;58:257.
• 3. Omsland TK, Emaus N, Tell GS, Magnus JH, Ahmed LA, Holvik K, et al. Mortality following the first hip fracture in Norwegian women and men (1999–2008). A NOREPOS study. Bone 2014;63:81-6.
• 4. Moon JY, Nagaraju D, Franchi F, Rollini F, Angiolillo DJ. The role of oral anticoagulant therapy in patients with acute coronary syndrome. Therapeutic Advances in Hematology. 2017:353-66. doi:10.1177/2040620717733691
• 5. The European Agency for the Evaluation of Medicinal Products. Guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk. CPMP/EWP/707/98 Rev. 1.2007. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500143764.pdf. Accessed 30 June 2015.
• 6. Quach LH, Jayamaha S, Whitehouse SL, Crawford R, Pulle CR, Bell JJ. Comparison of the Charlson Comorbidity Index with the ASA score for predicting 12-month mortality in acute hip fracture. Injury. 2020 ;51:1004-10. doi: 10.1016/j.injury.2020.02.074.
• 7. Wilson D, Cooke EA, McNally MA, Wilson HK, Yeates A, Mollan RA. Changes in coagulability as measured by thrombelastography following surgery for proximal femoral fracture. Injury. 2001;32:765-70.
• 8. Song K, Yao Y, Rong Z, Shen Y, Zheng M, Jiang Q. The preoperative incidence of deep vein thrombosis (DVT) and its correlation with postoperative DVT in patients undergoing elective surgery for femoral neck fractures. Arch Orthop Trauma Surg. 2016;136:1459-64
• 9. Karadağ B, Ikitimur B, Öngen Z. Perioperative management in patients receiving newer oral anticoagulant and antiaggregant agents. Turk Kardiyol Dern Ars. 2012;40:548-51.
• 10. Dargham BB, Baskar A, Tejani I, Cui Z, Chauhan S, Sum-Ping J, et al. Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention. Cardiovasc Revasc Med. 2019;20:805-11.
• 11. Leer-Salvesen S, Dybvik E, Ranhoff AH, Husebø BL, Dahl OE, Engesæter LB, et al. Do direct oral anticoagulants (DOACs) cause delayed surgery, longer length of hospital stay, and poorer outcome for hip fracture patients? Eur Geriatr Med. 2020;11:563-9.
• 12. Schuetze K, Eickhoff A, Dehner C, Gebhard F, Richter PH. Impact of oral anticoagulation on proximal femur fractures treated within 24 h - A retrospective chart review. Injury. 2019;50:2040-4.
• 13. Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018 4;362:k2505.
• 14. Collinge CA, Kelly KC, Little B, Weaver T, Schuster RD. The effects of clopidogrel (Plavix) and other oral anticoagulants on early hip fracture surgery. J Orthop Trauma 2012;26:568-73.
• 15. Feely MA, Mabry TM, Lohse CM, Sems SA, Mauck KF. Safety of clopidogrel in hip fracture surgery. Mayo Clin Proc. 2013;88:149-56.
• 16. Lin SY, Huang HT, Chou SH, Ho CJ, Liu ZM, Chen CH, et al. The Safety of Continuing Antiplatelet Medication Among Elderly Patients Undergoing Urgent Hip Fracture Surgery. Orthopedics. 2019;42:268-74. doi: 10.3928/01477447-20190723-02.
• 17. López S, da Casa C, Pablos-Hernández C, Pescador D, Díaz-Álvarez A, Asensio N, et al. The impact of antithrombotic therapy on surgical delay and 2-year mortality in older patients with hip fracture: a prospective observational study. Eur Geriatr Med. 2020 ;11:555-61. doi: 10.1007/s41999-020-00293-3.
• 18. Yang Z, Ni J, Long Z, Kuang L, Gao Y, Tao S. Is hip fracture surgery safe for patients on antiplatelet drugs and is it necessary to delay surgery? A systematic review and meta-analysis. J Orthop Surg Res. 2020 ;15:105. doi: 10.1186/s13018-020-01624-7.
• 19. Yoo MS, Zhu S, Jiang SF, Hammer HL, McBride WJ, McCarthy CM, et al. Association of Reversal of Anticoagulation Preoperatively on 30-Day Mortality and Outcomes for Hip Fracture Surgery. Am J Med. 2020;133:969-75. doi: 10.1016/j.amjmed.2020.01.002.
• 20. Yoon BH, Ko YS, Jang SH, Ha JK. Feasibility of Hip Fracture Surgery Using a No Transfusion Protocol in Elderly Patients: A Propensity Score-Matched Cohort Study. J Orthop Trauma 2017;31:414-9.
• 21. Simon GI, Craswell A, Thom O, Fung YL. Outcomes of restrictive versus liberal transfusion strategies in older adults from nine randomised controlled trials: a systematic review and meta-analysis. Lancet Haematol. 2017;4:465-74.
• 22. Menzies IB, Mendelson DA, Kates SL, Friedman SM. The impact of comorbidity on perioperative outcomes of hip fractures in a geriatric fracture model. Geriatr Orthop Surg Rehabil. 2012;3:129-34. doi: 10.1177/2151458512463392.
• 23. Roche JJ, Wenn RT, Sahota O, Moran CG. Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study. BMJ. 2005; 10;331(7529):1374. doi: 10.1136/bmj.38643.663843.55.
• 24. Lu Y, Uppal HS. Hip Fractures: Relevant Anatomy, Classification, and Biomechanics of Fracture and Fixation. Geriatr Orthop Surg Rehabil. 2019;10:2151459319859139. doi:10.1177/2151459319859139
• 25. Görmeli G, Korkmaz MF, Görmeli CA, Adanaş C, Karataş T, Şimşek SA. Comparison of femur intertrochanteric fracture fixation with hemiarthroplasty and proximal femoral nail systems. Ulus Travma Acil Cerrahi Derg. 2015;21(6):503-8. doi: 10.5505/tjtes.2015.96166.
• 26. Valentin N, Lomholt B, Jensen JS, Hejgaard N, Kreiner S. Spinal or general anaesthesia for surgery of the fractured hip? A prospective study of mortality in 578 patients. Br J Anaesth. 1986;58:284-91. doi: 10.1093/bja/58.3.284.
• 27. Davis FM, Woolner DF, Frampton C, Wilkinson A, Grant A, Harrison RT, et al. Prospective, multi-centre trial of mortality following general or spinal anaesthesia for hip fracture surgery in the elderly. Br J Anaesth. 1987 ;59:1080-8. doi: 10.1093/bja/59.9.1080.
• 28. Heidari SM, Soltani H, Hashemi SJ, Talakoub R, Soleimani B. Comparative study of two anesthesia methods according to postoperative complications and one month mortality rate in the candidates of hip surgery. J Res Med Sci. 2011;16:323-30.
• 29. Parker MJ, Griffiths R. General versus regional anaesthesia for hip fractures. A pilot randomised controlled trial of 322 patients. Injury. 2015;46:1562-6. doi: 10.1016/j.injury.2015.05.004.
• 30. Shin S, Kim SH, Park KK, Kim SJ, Bae JC, Choi YS. Effects of Anesthesia Techniques on Outcomes after Hip Fracture Surgery in Elderly Patients: A Prospective, Randomized, Controlled Trial. J Clin Med. 2020;9:1605. doi: 10.3390/jcm9061605. PMID: 32466360; PMCID: PMC7355551.
• 31. Ueoka K, Sawaguchi T, Goshima K, Shigemoto K, Iwai S, Nakanishi A. The influence of pre-operative antiplatelet and anticoagulant agents on the outcomes in elderly patients undergoing early surgery for hip fracture. J Orthop Sci 2019;24:830-5.
• 32. Cha YH, Lee YK, Koo KH, Wi C, Lee KH. Difference in Mortality Rate by Type of Anticoagulant in Elderly Patients with Cardiovascular Disease after Hip Fractures. Clin Orthop Surg 2019;11:15-20.
• 33. Lange N, Méan M, Stalder O, Limacher A, Tritschler T, Rodondi N, et al. Anticoagulation quality and clinical outcomes in multimorbid elderly patients with acute venous thromboembolism. Thromb Res 2019;177:10-6.